Abstract: Mammalian target of rapamycin (mTOR) is a kind of Ser/Thr kinase that exists in mammalian cells can regulate cell proliferation, migration and angiogenesis. mTOR including mTORC1 and mTORC2 two different complex forms. Originally developed as an anti-fungal agent, rapamycin and rapalogs were soon found to have powerful immunosuppressant properties and thus be valuable for preventing the progress of the artery atheromatous by inhibiting the function of mTORC1. But long-term rapalogs administration may increase the side actions such as mTORC1 resistance, mTORC2 inhibition, dyslipidemia. The clinical application of drug combination and dosing interval is in order to reduce the occurrence of adverse events.

Key words: Key words: Atherosclerosis, mTOR, rapamycin, rapalogs